Active Pharmaceutical Ingredient for Cancer Market Research Report - Global Forecast to 2027

Active Pharmaceutical Ingredient For Cancer Market Report: Information by Type (Tyrosine Kinase Inhibitor (Tinib), Proteasome Inhibitors (Parib), BRAF Kinase Inhibitors (Rafenib), Phosphatidylinositol 3-Kinase Inhibitors (Lisib), SMO Receptor Antagonists (Degib), Cyclin Dependent Kinase Inhibitors (Ciclib) and others), Indications (Blood Cancer, Skin Cancer, Lung Cancer, Breast Cancer, Pancreas Cancer, Others), End User (Pharmaceutical Companies, Research Organizations, Others) and Region (Americas, Europe, Asia-Pacific and Middle East ...

ID: MRFR/HC/6828-HCR | August 2022 | Region: Global | 164 Pages         

Table of Contents:

Chapter 1. Executive Summary

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.3 Assumptions

2.4 Limitations

Chapter 3. Research Methodology

3.1 Research Process

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

3.5 Forecast Model

Chapter 4. Market Dynamics

4.1 Overview

4.2 Drivers

4.3 Restraints

4.4 Opportunities

4.5 Pipeline Analysis

4.5 Macroeconomic Indicators

Chapter 5. Market Factor Analysis

5.1 Porterโ€™s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Opportunities

Chapter 6. Global Active Pharmaceutical Ingredient for Cancer Market, by Type

6.1 Overview

6.2 Tyrosine kinase inhibitor (Tinib)

6.2.1 Ponatinib

6.2.2 Brigatinib

6.2.3 Ruxolitinib

6.2.4 Erlotinib

6.2.5 Alectinib

6.2.6 Cobimetinib

6.2.7 Neratinib

6.2.8 Osimertinib

6.2.9 Acalabrutinib

6.2.10 Bosutinib

6.2.11 Crizotinib

6.2.12 Axitinib

6.2.13 Sunitinib

6.2.14 Ceritinib

6.2.15 Imatinib

6.2.16 Lapatinib

6.2.17 Afatinib

6.2.18 Cabozantinib

6.2.19 Dasatinib

6.2.20 Ibrutinib

6.2.21 Lenvatinib

6.2.22 Gefitinib

6.2.23 Others

6.3 Proteasome Inhibitors (Parib)

6.3.1 Olaparib

6.3.2 Rucaparib

6.3.3 Niraparib

6.4 BRAF Kinase Inhibitors (rafenib)

6.4.1 Sorafenib

6.4.2 Regorafenib

6.4.3 Vemurafenib

6.4.4 Dabrafenib

6.4.5 Enasidenib

6.4.6 Others

6.5 Phosphatidylinositol 3-kinase Inhibitors (Lisib)

6.5.1 Idelalisib

6.5.2 Copanlisib

6.6 SMO Receptor Antagonists (Degib)

6.6.1 Sonidegib

6.6.2 Vismodegib

6.7 Cyclin Dependent Kinase Inhibitors (Ciclib)

6.7.1 Palbociclib

6.7.2 Ribociclib

6.7.3 Abemaciclib

6.8 Others

โ€ƒ

Chapter 7. Global Active Pharmaceutical Ingredient for Cancer Market, by Indication

7.1 Overview

7.2 Blood Cancer

7.3 Skin Cancer

7.4 Lungs Cancer

7.5 Breasts Cancer

7.6 Pancreas Cancer

7.7 Others

Chapter 8. Global Active Pharmaceutical Ingredient for Cancer Market, by End User

8.1 Overview

8.2 Pharmaceutical Companies

8.3 Research Organizations

8.4 Others

Chapter 10. Global Active Pharmaceutical Ingredient for Cancer Market, by Region

10.1 Overview

10.2 Americas

10.2.1 North America

10.2.1.1 US

10.2.1.2 Canada

10.2.2 Latin America

10.3 Europe

10.3.1 Western Europe

10.3.1.1 Germany

10.3.1.2 France

10.3.1.3 Italy

10.3.1.4 Spain

10.3.1.5 UK

10.3.1.6 Rest of Western Europe

10.3.2 Eastern Europe

10.4 Asia-Pacific

10.4.1 Japan

10.4.2 China

10.4.3 India

10.4.4 Australia

10.4.5 South Korea

10.4.6 Rest of Asia-Pacific

10.5 Middle East & Africa

10.5.1 Middle East

10.5.2 Africa

Chapter 11. Company Landscape

11.1 Overview

11.2 Market Share Analysis

11.3 Key Development & Strategies

Chapter 12 Company Profiles

12.1 AbbVie

12.1.1 Company Overview

12.1.2 Product Overview

12.1.3 Financials Overview

12.1.4 Key Developments

12.1.5 SWOT Analysis

12.1.6 Key Strategies

12.2 Pfizer Inc.

12.3 Boehringer Ingelheim International GmbH

12.4 AstraZeneca

12.5 Novartis AG.

12.6 F. Hoffmann-La Roche AG

12.7 Bayer AG

12.8 Bristol-Myers Squibb Company

12.9 Eisai Co., Ltd

12.10 Johnson & Johnson

12.11 Merck Sharp & Dohme Corp.

12.12 Amgen Inc

12.13 Others

Chapter 13 Appendix

โ€ƒ

LIST OF TABLES

TABLE 1. ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET SYNOPSIS, 2020-2027

TABLE 2. ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET ESTIMATES AND FORECAST, 2020-2027 (USD MILLION)

TABLE 3. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET, BY REGION, 2020-2027 (USD MILLION)

TABLE 4. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET, BY TYPE, 2020-2027 (USD MILLION)

TABLE 5. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET, BY INDICATIONS, 2020-2027 (USD MILLION)

TABLE 6. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 7. NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET, BY TYPE, 2020-2027 (USD MILLION)

TABLE 8. NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET, BY INDICATIONS, 2020-2027 (USD MILLION)

TABLE 9. NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 10. US: ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET, BY TYPE, 2020-2027 (USD MILLION)

TABLE 11. US: ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET, BY INDICATIONS, 2020-2027 (USD MILLION)

TABLE 12. US: ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 13. CANADA: ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET, BY TYPE, 2020-2027 (USD MILLION)

TABLE 14. CANADA: ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET, BY INDICATIONS, 2020-2027 (USD MILLION)

TABLE 15. CANADA: ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 16. LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET, BY TYPE, 2020-2027 (USD MILLION)

TABLE 17. LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET, BY INDICATIONS, 2020-2027 (USD MILLION)

TABLE 18. LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 19. EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET, BY TYPE, 2020-2027 (USD MILLION)

TABLE 20. EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET, BY INDICATIONS, 2020-2027 (USD MILLION)

TABLE 21. EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 22. WESTERN EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET, BY TYPE, 2020-2027 (USD MILLION)

TABLE 23. WESTERN EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET, BY INDICATIONS, 2020-2027 (USD MILLION)

TABLE 24. WESTERN EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 25. EASTERN EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET, BY TYPE, 2020-2027 (USD MILLION)

TABLE 26. EASTERN EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET, BY INDICATIONS, 2020-2027 (USD MILLION)

TABLE 27. EASTERN EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 28. ASIA-PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET, BY TYPE, 2020-2027 (USD MILLION)

TABLE 29. ASIA-PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET, BY INDICATIONS, 2020-2027 (USD MILLION)

TABLE 30. ASIA-PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 31. MIDDLE EAST & AFRICA: ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET, BY TYPE, 2020-2027 (USD MILLION)

TABLE 32. MIDDLE EAST & AFRICA: ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET, BY INDICATIONS, 2020-2027 (USD MILLION)

TABLE 33. MIDDLE EAST & AFRICA: ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET, BY END USER, 2020-2027 (USD MILLION)

LIST OF FIGURES

FIGURE 1. RESEARCH PROCESS

FIGURE 2. SEGMENTATION FOR GLOBAL ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET

FIGURE 3. MARKET DYNAMICS FOR GLOBAL ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET

FIGURE 4. ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET SHARE, BY TYPE, 2020

FIGURE 5. ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET SHARE, BY INDICATIONS, 2020

FIGURE 6. ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET SHARE, BY END USER, 2020

FIGURE 7. ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET SHARE, BY REGION, 2020

FIGURE 8. NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET SHARE, BY COUNTRY, 2020

FIGURE 9. EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET SHARE, BY COUNTRY, 2020

FIGURE 10. ASIA-PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET SHARE, BY COUNTRY, 2020

FIGURE 11. MIDDLE EAST & AFRICA: ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET SHARE, BY REGION, 2020

FIGURE 12. ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET: COMPANY SHARE ANALYSIS, 2020 (%)

FIGURE 13. ABBVIE: KEY FINANCIALS

FIGURE 14. ABBVIE: SEGMENTAL REVENUE

FIGURE 15. ABBVIE: GEOGRAPHICAL REVENUE

FIGURE 16. PFIZER INC: KEY FINANCIALS

FIGURE 17. PFIZER INC: SEGMENTAL REVENUE

FIGURE 18. PFIZER INC: GEOGRAPHICAL REVENUE

FIGURE 19. PFIZER INC: KEY FINANCIALS

FIGURE 20. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: SEGMENTAL REVENUE

FIGURE 21. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: GEOGRAPHICAL REVENUE

FIGURE 22. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: KEY FINANCIALS

FIGURE 23. ASTRAZENECA: SEGMENTAL REVENUE

FIGURE 24. ASTRAZENECA: GEOGRAPHICAL REVENUE

FIGURE 25. ASTRAZENECA: KEY FINANCIALS

FIGURE 26. NOVARTIS AG: SEGMENTAL REVENUE

FIGURE 27. NOVARTIS AG: GEOGRAPHICAL REVENUE

FIGURE 28. NOVARTIS AG.: KEY FINANCIALS

FIGURE 29. F. HOFFMANN-LA ROCHE AG.: SEGMENTAL REVENUE

FIGURE 30. F. HOFFMANN-LA ROCHE AG.: GEOGRAPHICAL REVENUE

FIGURE 31. F. HOFFMANN-LA ROCHE AG: KEY FINANCIALS

FIGURE 32. BAYER AG: SEGMENTAL REVENUE

FIGURE 33. BAYER AG: GEOGRAPHICAL REVENUE

FIGURE 34. BAYER AG: KEY FINANCIALS

FIGURE 35. BRISTOL-MYERS SQUIBB COMPANY: SEGMENTAL REVENUE

FIGURE 36. BRISTOL-MYERS SQUIBB COMPANY: GEOGRAPHICAL REVENUE

FIGURE 37. BRISTOL-MYERS SQUIBB COMPANY: KEY FINANCIALS

FIGURE 38. EISAI CO., LTD: SEGMENTAL REVENUE

FIGURE 39. EISAI CO., LTD: GEOGRAPHICAL REVENUE

FIGURE 40. EISAI CO., LTD: KEY FINANCIALS

FIGURE 41. JOHNSON & JOHNSON: SEGMENTAL REVENUE

FIGURE 42. JOHNSON & JOHNSON: GEOGRAPHICAL REVENUE

FIGURE 43. JOHNSON & JOHNSON: KEY FINANCIALS

FIGURE 44. MERCK SHARP & DOHME CORP.: SEGMENTAL REVENUE

FIGURE 45. MERCK SHARP & DOHME CORP.: GEOGRAPHICAL REVENUE

FIGURE 46. MERCK SHARP & DOHME CORP.: KEY FINANCIALS

FIGURE 47. AMGEN INC: SEGMENTAL REVENUE

FIGURE 48. AMGEN INC: GEOGRAPHICAL REVENUE

FIGURE 49. AMGEN INC: KEY FINANCIALS


Active Pharmaceutical Ingredient for Cancer Market Speak to Analyst Request a Free Sample

Active Pharmaceutical Ingredient for Cancer Market Synopsis


Active Pharmaceutical Ingredient (API) for Cancer Market is expected to register a CAGR of 8.1% and is anticipated to reach USD 34,300.00 Million by 2025. API for cancer market, including conventional syringes, needle-free injectors, and auto and pen injectors have been extensively utilized for the administration of drugs to treat medical conditions ranging from cancer to autoimmune disorders. The market for API for cancer has witnessed continuously rising R&D. As a result, the active pharmaceutical ingredient for cancer market is fragmented into various advanced products as per the molecules. Following the illustrated course, it is projected that increasing prevalence of cancer, growing technologies for treatments of various types of cancer, and rising FDA approvals of anticancer drugs drives the market growth. However, side effects associated with the medication are estimated to restrain the market growth during the forecast period.


Active Pharmaceutical Ingredient for Cancer Market Dynamics


The active pharmaceutical ingredient for cancer market is driven by increasing prevalence of cancer drives the market growth. According to the statistical report published by the World Health Organization (WHO) in 2018, around 18.1 million new cases of cancers were estimated reported worldwide. This indicates a potential for growth in the global API for cancer market.


The other factors that are driving the global API for cancer market are growing technologies for treatments of various types of cancer, and rising FDA approvals of anticancer drugs, growing demand for newly developed small molecules drugs, and others.


Global Active Pharmaceutical Ingredient for Cancer Market Size, by Indication, 2018 & 2025 (USD Million)  Active Pharmaceutical Ingredient for Cancer Market


Source: MRFR Analysis


Active Pharmaceutical Ingredient for Cancer Market Segmentation


The global API for cancer market has been segmented into by type, indications, and end users.


Based on type it is segmented into tinib, parib, rafenib, lisib, degib, ciclib, and others


Based on indication, it is segmented into blood cancer, skin cancer, lungs cancer, breasts cancer, pancreas cancer, others.


Based on end user, the market is segmented into pharmaceutical companies, research organizations, others.


Active Pharmaceutical Ingredient for Cancer Market Key Players


The prominent players in the global API for cancer market are AbbVie, Pfizer Inc, Boehringer Ingelheim International GmbH, AstraZeneca, Novartis AG., F. Hoffmann-La Roche AG, Bayer AG, Bristol-Myers Squibb Company, Eisai Co., Ltd, Johnson & Johnson, Merck & Co. Inc., Amgen Inc., and others.


Global Active Pharmaceutical Ingredient for Cancer Market Share, by Region, 2018 (%)  Active Pharmaceutical Ingredient for Cancer Market


Source: MRFR Analysis


Active Pharmaceutical Ingredient for Cancer Market Regional Analysis


The global API for cancer market, based on region, is divided into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas is anticipated to dominate the global API for cancer market owing to the rising awareness about the condition and high healthcare expenditure. The Americas is expected to reach USD 34,300.00 million by 2025 at a CAGR of 8.1% from 2018 to 2025. The Americas region accounted largest regional market owing to the growing biotechnology industry, the growing prevalence of cancer, and a highly developed healthcare sector.  


Europe accounted for the second-largest market share in 2018 due to extensive R&D for healthcare, increasing funding, and growing adoption of the technology within the region.


On the other hand, the Middle East and Africa is expected to observe slow growth due to less exposure to healthcare services, lack of awareness, and stringent government rules and regulations.


Key Updates



  • In May 2019, Eli Lilly and Company received US Food and Drug Administration approval for its drug Cyramza (ramucirumab) a human VEGFR2 antagonist. It is a recombinant molecule of the human IgG1 monoclonal antibody.



  • In April 2019 Johnson & Johnson received US Food and Drug Administration approval for product Balversa (erdafitinib), oral fibroblast growth factor receptor (FGFR) kinase inhibitor.


Market Segmentation


Global Active Pharmaceutical Ingredient for Cancer Market, by Type



  • Tyrosine Kinase Inhibitor (Tinib)


    • Ponatinib

    • Brigatinib

    • Ruxolitinib

    • Erlotinib

    • Alectinib

    • Cobimetinib

    • Neratinib

    • Osimertinib

    • Acalabrutinib

    • Bosutinib

    • Crizotinib

    • Axitinib

    • Sunitinib

    • Ceritinib

    • Imatinib

    • Lapatinib

    • Afatinib

    • Cabozantinib

    • Dasatinib

    • Ibrutinib

    • Lenvatinib

    • Gefitinib

    • Others


  • Proteasome Inhibitors (Parib)


    • Olaparib

    • Rucaparib

    • Niraparib

    • BRAF Kinase Inhibitors (rafenib)

    • Sorafenib

    • Regorafenib

    • Vemurafenib

    • Dabrafenib

    • Enasidenib

    • Others


  • Phosphatidylinositol 3-Kinase Inhibitors (Lisib)


    • Idelalisib

    • Copanlisib


  • SMO Receptor Antagonists (Degib)


    • Sonidegib

    • Vismodegib


  • Cyclin Dependent Kinase Inhibitors (Ciclib)


    • Palbociclib

    • Ribociclib

    • Abemaciclib


  • Others


Global API for Cancer Market, by Indication



  • Blood Cancer

  • Skin Cancer

  • Lungs Cancer

  • Breasts Cancer

  • Pancreas Cancer

  • Others


Global Active Pharmaceutical Ingredient for Cancer Market, by End User



  • Pharmaceutical Companies

  • Research Organizations

  • Others


Global Active Pharmaceutical Ingredient for Cancer Market, by Region



  • Americas


    • North America


      • US

      • Canada


    • Latin America




  • Europe


    • Western Europe


      • Germany

      • UK

      • France

      • Italy

      • Spain

      • Rest of Western Europe


    • Eastern Europe




  • Asia-Pacific


    • China

    • Japan

    • India

    • Australia

    • South Korea

    • Rest of Asia-Pacific




  • Middle East & Africa


    • Middle East

    • Africa



Available Additional Customizations



  • Additional Companies

  • Supply & Demand Analysis


Intended Audience



  • Pharmaceutical Companies

  • Hospitals and Clinics

  • Regulatory Agencies

  • Research Institutes



Speak to Analyst Ask for Customization